

Research Article

Open Access

Formulation and Optimization of Controlled Porosity Osmotic Pump Tablets of Lamivudine using Sodium Chloride as Osmogen for the Treatment of AIDS

Chinmaya Keshari Sahoo¹, Nalini Kanta Sahoo^{2*}, Surepalli Ram Mohan Rao³ and Muvvala Sudhakar⁴

¹Ph.D Scholar, Department of Pharmaceutics, Faculty of Pharmacy, University College of Technology, Osmania University, Hyderabad, Telangana, India

²Professor & HOD, Department of Pharmaceutical Analysis and Quality assurance, MLR Institute of Pharmacy, Dundigal, Medchal, Telangana, India

³Professor, Mekelle Institute of Technology, Mekelle University, Mekelle, Ethiopia

⁴Professor and Principal, Department of Pharmaceutics, Malla Reddy College of Pharmacy, Maisammaguda, Secunderabad, Telangana, India

Article Info

*Corresponding author:

Nalini Kanta Sahoo

Professor & HOD

Department of Pharmaceutical Analysis and Quality Assurance

MLR Institute of Pharmacy

Dundigal, Medchal

Telangana, India

Tel: 9550741536

Email: sahoonalinini@gmail.com

Received: October 24, 2018

Accepted: October 29, 2018

Published: October 31, 2018

Citation: Sahoo CK, Sahoo NK, Rao SRM, Sudhakar M. Formulation and Optimization of Controlled Porosity Osmotic Pump Tablets of Lamivudine using Sodium Chloride as Osmogen for the Treatment of AIDS. *Madridge J Nov Drug Res.* 2018; 2(1): 94-101. doi: 10.18689/mjndr-1000114

Copyright: © 2018 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published by Madridge Publishers

Abstract

The present study was undertaken to develop controlled porosity osmotic pump tablets of lamivudine a nucleoside reverse transcriptase inhibitor for the treatment of acquired immune deficiency syndrome (AIDS). The tablets were prepared by wet granulation method using HPMC E5LV, and osmogen was principal ingredients a dose of 300 mg once daily. The coating solution of core tablets were prepared by using cellulose acetate, poly ethylene glycol of different grades, sorbitol and acetone to quantity sufficient for different batches. The prepared tablets were evaluated for pre compression parameters, post compression parameters, *in vitro* drug release study and scanning electron microscopy study. Among developed formulations LS4 batch show 98.26% drug release in 12 hrs. The *in vitro* release kinetics were analyzed for different batches by different pharmacokinetic models such as zero order, first order, Higuchi, Korsmeyer Peppas and Hixon Crowell model. The results of optimized formulation follow Higuchi kinetics and which is independent of the pH and agitation intensity. Short term stability study (at 40 ± 2°C/75 ± 5% RH for three months) on the best formulation indicated that there was no significant changes in thickness, friability, weight variation, drug content and *in vitro* drug release.

Keywords: AIDS; Wet granulation; *In vitro* drug release; Stability study.

Introduction

The discovery of HIV as the causative agent of AIDS by Sinoussi et al. in 1983 [1], HIV/AIDS is a major threat to population health in the world. Over the past 35 years AIDS is spreading like a pandemic disease and creating major global health problems in the world. WHO estimate in 2015 showed that 36.7 million people globally [2] were living with HIV, AIDS killed 1.1 million people died from AIDS related illnesses and 35 million people have died from AIDS related illness since start from epidemic. In AIDS patient experiences infection in immune system causing decline CD4+ cell count of less than 200 cells/μL in blood. The most common initial conditions of AIDS are pneumocystis pneumonia (40%), cachexia in the form of HIV wasting syndrome (20%), respiratory tract infections and esophageal candidiasis. Opportunistic infections may be caused by bacteria, viruses, fungi and parasites. These infections affect nearly every organ system, e.g. brain, eye, liver, genitals, skin etc. Patients with AIDS have an increased risk of developing various viral

induced cancers including Kaposi's sarcoma. Symptoms occur in 40-90% of cases and most commonly include fever, large tender lymph nodes, throat inflammation, a rash, headache, sores of the mouth and genitals [3], etc. The transmission of AIDS is due to via unprotected sexual intercourse (including anal and even oral sex), contaminated blood transfusions, hypodermic needles and from mother to child during pregnancy, delivery or breastfeeding. The management of AIDS can be controlled by antiretroviral therapy, male circumcision, needle exchange program, use of diaphragms, topical protection, use of condoms and alternative medicine.

Oral route is the most convenient route and most extensively used for the administration of various drugs. Oral conventional doses are usually administered 2 or more than 2 times daily which causes a large fluctuations in drug plasma concentration and may cause side effects. Hence controlled drug delivery systems are used to avoid these limitations in conventional drug delivery system. Controlled release dosage forms [4] provide prolong action of drugs and offer continuous release of their active ingredients at predetermined rate and predetermined time of zero order drug release. Among several controlled drug delivery systems osmotic controlled drug delivery system (OCDDS) utilizes principle of osmotic pressure for controlled delivery of active ingredients. OCDDS can deliver the drug in a large extent and the delivery nature is independent of the physiological factors of gastrointestinal tract, independent of pH, hydrodynamic condition of the body and agitational intensity.

Current Highly active antiretroviral therapy (HAART) allows controlling viral replication of HIV-1. The present study is to develop controlled porosity osmotic pump tablets of lamivudine. CPOP tablet is a novel drug delivery system with eternally drug delivery rate as characteristic and controlled with the osmotic pressure difference between inside and outside of SPM as drug delivery power. CPOP tablets were developed where the delivery orifices were formed by the incorporation of a leachable component in SPM. The core is coated with cellulose acetate containing *in situ* micro pore former sorbitol. To increase drug release sodium chloride was chosen as osmotic agent who can generate high osmotic pressure gradient to deliver poorly or moderately water soluble drugs. Once CPOP tablets come in contact with the aqueous environment [5] of biological system the water soluble component dissolves and an osmotic pumping system is created in the core. Hence water diffuses into the core through the micro porous membrane setting up an osmotic gradient and thereby controlling the release of drug. The rate of drug delivery depends upon the factors such as water permeability of the semi permeable membrane, osmotic pressure of core formulation, thickness and total area of coating.

Lamivudine is a synthetic nucleoside analogue and is phosphorylated intra cellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase resulting in DNA chain termination [6]. The

present research aimed to design CPOP tablets of lamivudine by wet granulation method containing dose of 300 mg once daily. Lamivudine has bioavailability of 86%, protein binding of 36% and the biological half life is between 5-7 hrs. Hence it can be given to control the concentration of drug at the site of action. The main objective of the present study was to develop controlled porosity-based osmotically controlled release tablets of lamivudine.

Materials and Methods

Materials

Lamivudine was obtained from Hetero Drugs Pvt. Ltd. India., Sodium chloride and mannitol was obtained from Qualigens Fine Chemicals, India. Cellulose acetate (CA) was obtained from Eastman Chemical Inc, Kingsport, TN. Sorbitol, magnesium stearate, talc, HPMCE5LV and polyethylene glycol (PEG) 400, 600, 4000, 6000 were purchased from S.D. Fine Chemicals Ltd, Mumbai, India., Microcrystalline cellulose (MCC) and starch were purchased from Signet Pharma, Mumbai, India. All other solvents and reagents used were of analytical grade.

Compatibility studies

Fourier Transform Infrared Spectroscopy (FTIR) [7]: In this method individual samples, individual excipients and the mixture of drug and excipients were ground mixed thoroughly with potassium bromide (1:100) for 3-5 mins in a mortar and compressed into disc by applying pressure of 10 kg/cm in hydraulic press. The pellet was kept in the sample holder and scanned from 4000 to 400 cm^{-1} in FTIR spectrophotometer (Bruker, Germany).

Differential Scanning Calorimetry (DSC): Physical mixtures [8] of drug and individual excipients in the ratio of 1:1 were taken and examined in DSC (Shimadzu DSC-50, Japan). The sample pan was crimped for effective heat conduction and scanned in the temperature range of 50-300°C. Heating rate of 20°C min^{-1} was used and the thermogram obtained was reviewed for evidence of any interactions. Then the thermograms were compared with pure samples versus optimized formulation.

Methods

Preparation of osmotic pump tablets: The tablets were prepared by wet granulation [9] technique. Required quantities of ingredients mentioned in table-1 were passed through sieve No.30 and lubricant and glidant were passed through sieve No.80. The ingredients were manually blended homogeneously in a mortar by way of geometric dilution except lubricant (magnesium stearate), glidant (talc). The mixture was moistened with aqueous solution and granulated through sieve No.30 and dried in a hot air oven at 60°C for sufficient (3-4 hrs). The dried granules were sifted through sieve No.30 and mixed with talc and magnesium stearate. The homogenous blend was then compressed into round tablets with standard concave punches using 10 station rotary compression machines (Mini press, Karnavati, India).

Table 1. Composition of osmotic pump lamivudine tablets

Ingredients (mg)	LS1	LS2	LS3	LS4	LD5
LM	300	300	300	300	300
MCC	190	165	140	115	215
Starch	25	25	25	25	25
HPMC E5LV	100	100	100	100	100
Sodium chloride	25	50	75	100	0
Magnesium stearate	5	5	5	5	5
Talc	5	5	5	5	5
Total weight (mg)	650	650	650	650	650

Coating of core tablets [10]: The coating solution was prepared taking required ingredients from table 2 and acetone was added quantity sufficient maintaining proper viscosity of solution. The coatings of tablets were performed by spray pan coating in a perforated pan (GAC-205, Gansons Ltd, Mumbai, India). Hot air is supplied to tablet bed by rotating lower speed 5-8 rpm initially. The coating of tablets was carried out with the rotation speed of 10-12 rpm. The spray rate and atomizing air pressure were 4-6 ml/min and 1.75 kg/cm² respectively. Inlet and outlet air temperature were 50°C and 40°C respectively. Coated tablets were dried at 50°C for 12 hrs.

Table 2. Coating composition for controlled porosity osmotic pump tablets

Formulation code	CA (g)	PEG 400 (g)	PEG 600 (g)	PEG 4000 (g)	PEG 6000 (g)	Sorbitol (g)	Acetone (mL)
LS1	6	2	0	0	0	0	300
LS2	6	0	2	0	0	0.4	300
LS3	6	0	0	2	0	0.8	300
LS4	6	0	0	0	2	1.2	300
LD5	6	0	0	0	0	1.2	300

Evaluation of Controlled Porosity Osmotic Pump Tablets

Pre compression parameters of osmotic pump tablets [11]

Angle of repose θ : The angle of repose was determined by the funnel method. The accurately weighed powder blend was taken in a funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touched the apex of the heap of the powder blend. The blends were allowed to flow freely onto the surface (Table 3). The diameter of the powder cone was measured. Angle of repose is calculated using the following equation:

$$\tan \theta = h/r \quad (1)$$

$$\theta = \tan^{-1}(h/r) \quad (2)$$

Where θ is the angle of repose, h is the height of heap in cm and r is the radius of the circular support (cone) in cm.

Bulk density (e_b): Bulk density is determined by pouring the granules into a graduated cylinder of bulk density apparatus (Sisco, India). The bulk volume (V_b) and mass (m) of the granules is determined. The bulk density is calculated by using the following formula.

$$e_b = \frac{m}{V_b} \quad (3)$$

Tapped density (e_t): The measuring cylinder containing

known mass of granules blend is tapped 1000 times for a fixed time in bulk density apparatus (Sisco, India). The minimum volume occupied in the cylinder (V_t) and mass of the granules (m) is measured. The tapped density is measured by using the following formula.

$$e_t = \frac{m}{V_t} \quad (4)$$

Compressibility index (Carr's index): The compressibility index determines the flow property characteristics of granules developed by Carr. The percentage compressibility of granules is a direct measure of the potential powder arch and stability (Table 3). The Carr's index can be calculated by the following formula.

$$\% \text{ Carr's index} = \frac{e_t - e_b}{e_t} \times 100 \quad (5)$$

Where e_t is the tapped density of granules and e_b is bulk density of granules.

Hausner's ratio (H_R): Hausner's ratio is used for the determination of flow properties of granules (Table 3). The ratio can be calculated by taking the ratio of tapped density to the ratio of bulk density.

$$H_R = \frac{e_t}{e_b} \quad (6)$$

Table 3. Scale of flowability determined by different methods [12].

Flow property	Angle of repose	Compressibility index	Hausner's ratio
Excellent	25-30	≤ 10	1.00-1.11
Good	31-35	11-15	1.12-1.18
Fair	36-40	16-20	1.19-1.25
Passable	41-45	21-25	1.26-1.34
Poor	46-55	26-31	1.35-1.45
Very poor	56-65	32-37	1.46-1.59
Very very poor	>66	>38	>1.6

Post compression parameters of controlled porosity osmotic pump tablets [13]

Thickness: The thickness of individual tablets is measured by using vernier caliper (Mitutoyo Corp., Japan) which gives the accurate measurement of thickness in mm. The limit of the thickness deviation of each tablet is $\pm 5\%$.

Measurement of coat thickness: After dissolution the film was isolated from the tablets and dried at 40°C for 1 hr. Thickness was measured by using electronic digital calipers (Mitutoyo Corp., Japan) and mean values were taken.

Hardness: The hardness of tablets can be determined by using Monsanto hardness tester (Sisco, India) and measured in terms of kg/cm².

Friability: Friability of tablets was performed in a Roche friabilator (Sisco, India). Twenty tablets of known weight (W_0) were de-dusted in plastic chamber of friabilator for a fixed time of 25 rpm for 4 minutes and weighed again of weight (W). The percentage of friability was calculated using the following equation.

$$\% \text{ Friability} = F = \left(1 - \frac{W}{W_0}\right) \times 100 \quad (7)$$

Where, W_0 and W are the weight of the tablets before and after the test respectively.

Weight variation test [14]

The weight variation test is done by weighing 20 tablets individually calculating the average weight and comparing the individual tablet weights to the average. The percentage weight deviation was calculated and then compared with USP specifications.

Uniformity of drug content test

Ten tablets from each batch of CPOP formulations were taken and triturated to form powder. The powder weight equivalent to one tablet was dissolved in a 100 ml volumetric flask filled with 0.1N HCl using magnetic stirrer for 24 hr. Solution was filtered through Whatman filter paper No.1 diluted suitably and analyzed spectrophotometrically.

Diameter of tablet

The diameter of individual tablets is measured by using vernier caliper (Mitutoyo Corp., Japan) which gives the accurate measurement of diameter in mm.

In vitro dissolution studies

The *in vitro* dissolution studies were carried out using USP apparatus type II (Lab India 8000) at 75 rpm. For the first 2 hr the dissolution medium was 0.1N HCl (pH 1.2) and phosphate buffer pH 6.8 from 3-12 hr (900 ml), maintained at $37 \pm 0.5^\circ\text{C}$. At each time point 5 ml of sample was withdrawn and it was replaced with 5 ml of fresh medium. The drug release at different time interval was measured by UV-visible spectrophotometer (UV-1800, Shimadzu, Japan).

In vitro drug release kinetic studies [15,16]

In order to investigate the mode of release from tablets, the release data of optimized formulation was analyzed zero order kinetics, first order kinetics, Higuchi model, Korsmeyer-Peppas and Hixson-Crowell equations.

Effect of osmogen concentration [17]

To check the effect of osmogen concentration on drug release formulations were prepared with different concentration of osmotic agents and all other parameters of tablet kept constant. The drug release was compared with the different osmogen concentration of formulated batches by using USP-II dissolution apparatus.

Effect of pore former concentration [18]

Different concentrations of pore former were used in semi permeable membrane formation. In order to compare the effect of pore former on *in vitro* release profile as well as number of formation of micropores were compared.

Effect of membrane thickness [19]

Tablets with varying coating thicknesses were prepared to demonstrate the effect of coating thickness on drug release. The drug release rate was measured using 0.1 N HCl and phosphate buffer pH 6.8 as a dissolution medium.

Effect of osmotic pressure [20]

To increase the osmotic pressure of the release media pre-equilibrated to $37^\circ\text{C} \pm 1^\circ\text{C}$ temperature and osmotically effective solute mannitol was added to produce 30 atm, 60

atm and 90 atm respectively. The drug release rate was tested and compared for various dosage forms.

Effect of pH [21]

In order to study the effect of pH of release medium in the drug release of optimized formulation, the *in vitro* release study was carried in dissolution media having different pH media. Dissolution can be carried in 900 ml of 0.1 N HCl, pH 6.8 phosphate buffer and pH 7.4 phosphate buffer in USP type II dissolution apparatus in 75 rpm. The temperature was maintained at $37 \pm 0.5^\circ\text{C}$. The release was studied at predetermined time intervals.

Effect of agitation intensity [22]

To study the effect of agitation intensity on drug release, optimized formulation was subjected to dissolution at various rotation speeds. Dissolution was carried out in USP-II (Paddle) at 50, 100 and 150 rpm. The samples were withdrawn at predetermined intervals and analyzed by UV spectrometer.

Scanning Electron Microscopy (SEM) [23]

In order to observe the mechanism of drug release from the developed formulations surface coated tablets before and after dissolution studies was examined using scanning electron microscope. Scans were taken at an excitation voltage (KV) in SEM fitted with ion sputtering device.

Accelerated stability studies [24]

The packed tablets in air tight container were placed in stability chambers (Thermo lab Scientific equipment Pvt. Ltd., Mumbai, India) maintained at $40 \pm 2^\circ\text{C}/75 \pm 5\%$ RH conditions for accelerated testing) for 3 months. Tablets were periodically removed and evaluated for physical characteristics, drug content, *in-vitro* drug release etc.

Results and Discussion

FTIR studies

The study of the FTIR spectra of lamivudine demonstrated that the characteristic absorption peaks for the C-H stretching at 2843.83 cm^{-1} , N-H bending at 1640.32 cm^{-1} , C-N stretching at 1010.71 cm^{-1} , O-H in plane bending at 1054.55 cm^{-1} and amine group stretching at 3326.6 cm^{-1} . This further confirms the purity of lamivudine.

The major peaks of HPMCE5LV were found at 3880.71, 3810.87, 3713.83, 3669.20, 3566, 3117.03, 3066.96, 2982.59, 2887.86, 2847.2, 2803.12, 2710.75, 2618.99, 2444.13, 2335.14, 2068.70, 1661.47, 1536.52, 1500.67, 1424.62, 1071.87, 781.05 and 584.97 cm^{-1} . The major peaks of sodium chloride were found at 3398.38, 2133.90, 2062.19, 1787.75, 1187.17, 906.53 and 634.66 cm^{-1} . In the optimized formulation containing sodium chloride of osmotic pump (LS4) peak at 3669.81, 3054.80, and 795.27 cm^{-1} were due to presence of the polymer HPMCE5LV. In the formulation the peaks present due to sodium chloride were 1779.97 and 613.23 cm^{-1} . Peaks at 2124.12, and 1649.61 cm^{-1} were due to presence of the drug lamivudine in the optimized formulation. So from the study it can be concluded that the major peaks of drug 2124.12, and

1649.61 cm^{-1} remain intact and no interaction was found between the drug, polymer and osmogen. Hence drug-excipient mixture reveals that here is no incompatibility was observed between lamivudine (Figures 1 and 2).




Figure 1. FTIR spectroscopy study of pure Lamivudine




Figure 2: FTIR spectroscopy study of LS4

DSC Thermograms

From the figure 3 it was found that the endothermic peak of lamivudine was at 162.2°C. The endothermic peak of LS4 formulation (Figure 4) was observed at 161.3°C. No significant change in the endotherm was observed between drug and formulation. From the DSC thermograms it was clear that no specific interaction between the drug and excipients used in present formulation.




Figure 3. DSC thermo gram of Lamivudine




Figure 4. DSC thermo gram of LS4

Pre compression parameters

All the compressible excipients for various batches were evaluated for angle of repose, bulk density, tapped density, Carr's index and Hausner's Ratio. The angle of repose of pre-compression blends of various batches was in the range of 24.96 ± 0.06 to 28.17 ± 0.05 . The bulk density of pre-compression blends was found to be in the range of 0.502 ± 0.12 to 0.528 ± 0.12 gm/ml, tapped density in the range of 0.537 ± 0.04 to 0.562 ± 0.11 gm/ml, the Carr's index values were in the range of 5.77 ± 0.02 to 7.72 ± 0.09 , and Hausner's ratio values were ranges of 1.06 ± 0.02 to 1.08 ± 0.11 . It is given in table 4.

Table 4. Pre compression parameters of LM formulations

Formulation code	Angle of repose (degree) ^a ± S.D	Bulk density (g/ml) ^a ± S.D	Tapped density (g/ml) ^a ± S.D	Carr's Index (%) ^a ± S.D	Hausner's Ratio ^a ± S.D
LS1	28.17 ± 0.05	0.502 ± 0.12	0.544 ± 0.14	7.72 ± 0.09	1.08 ± 0.11
LS2	27.16 ± 0.14	0.509 ± 0.12	0.545 ± 0.11	6.60 ± 0.09	1.07 ± 0.16
LS3	28.12 ± 0.13	0.513 ± 0.13	0.546 ± 0.12	6.04 ± 0.01	1.06 ± 0.06
LS4	24.96 ± 0.06	0.506 ± 0.08	0.537 ± 0.04	5.77 ± 0.02	1.06 ± 0.02
LD5	26.19 ± 0.11	0.528 ± 0.12	0.562 ± 0.11	6.05 ± 0.14	1.06 ± 0.09

N.B-All values are expressed as mean ± S.D, ^an=3.

Post compression parameters

All the post compression parameters for various batches evaluated accordingly such as thickness, coat thickness, hardness, friability, weight variation, drug content and diameter of tablet etc. The thickness of formulated tablets was found to be in the range of 3.502 ± 0.02 to 3.569 ± 0.03 mm, coat thickness in the range of 100.3 ± 2.4 to 250.6 ± 2.9 μm, the hardness values were in the range of 7.6 ± 0.04 to 8.3 ± 0.12 kg/cm², the friability values were in range of 0.12 ± 0.12 to 0.20 ± 0.14 , average weight of tablet was in the range of 649.9 ± 1.4 to 651.8 ± 1.2 mg, drug content of tablet was in the range of 98.17 ± 1.05 to 100 ± 1.14 and diameter of tablets values were ranges of 11.98 ± 0.04 to 12.29 ± 0.03 mm. It is mentioned in table 5.

Table 5. Post compression parameters of controlled porosity osmotic pump tablets

Formulation code	Thickness (mm) ^a ± S.D	Coat thickness (μm) ^b ± S.D	Hardness (kg/cm ²) ^a ± S.D	% Friability (%) ^b ± S.D	Average wt. of tablet (mg) ^b ± S.D	% Drug content (%) ^a ± S.D	Diameter (mm) ^a ± S.D
LS1	3.563 ± 0.04	250.6 ± 2.9	7.6 ± 0.04	0.20 ± 0.14	649.9 ± 1.4	99.74 ± 1.11	11.98 ± 0.04
LS2	3.569 ± 0.03	200.4 ± 3.1	7.8 ± 0.05	0.17 ± 0.12	650.9 ± 1.3	98.17 ± 1.05	12.21 ± 0.05
LS3	3.568 ± 0.04	150.3 ± 2.5	8.1 ± 0.16	0.13 ± 0.11	651.8 ± 1.2	98.438 ± 1.06	12.16 ± 0.03
LS4	3.502 ± 0.02	100.3 ± 2.4	8.3 ± 0.12	0.12 ± 0.14	650.02 ± 1.3	100 ± 1.14	12.03 ± 0.01
LD5	3.509 ± 0.01	150.5 ± 2.6	8.0 ± 0.02	0.12 ± 0.12	650.07 ± 1.03	98.958 ± 1.06	12.29 ± 0.03

N.B - All values are expressed as mean ± S.D, ^an=10, ^bn=20.

In vitro drug dissolution study

The *in vitro* drug release characteristics were studied in 900 ml of 0.1 N HCl (pH 1.2) for a period of first 2 hrs and 3 to 12 hrs in phosphate buffer pH 6.8 using USP type II dissolution apparatus (Paddle type). The cumulative percentage drug release for LS1, LS2, LS3, LS4 and LD5 were 91.92, 92.48, 93.71, 98.26 and 85.89% respectively of lamivudine at the end of 12 hrs. It is shown in figure 5. The same figure gives about effect of osmogen concentration, pore former and membrane thickness.




Figure 5. *In vitro* release profiles showing lamivudine release from various fabricated formulations LS1-LD5

Kinetic model

The drug release kinetics from the porous osmotic pump tablet, the *in vitro* release data were analyzed by zero order, first order, Higuchi and Korsmeyer and Peppas equations and Hixson-Crowell equation. The optimized formulation is showing highest regression values (R^2) in Higuchi model (0.984) than zero order and first order. Hence the drug release follows Higuchi kinetics. The n value for optimized formulation is 0.369 ($n < 0.45$), hence it follows Fickian diffusion mechanism. It is indicated in table 6.

Table 6. Fitting of IVDR data in various mathematical models

Models	Zero order		First order		Higuchi		Korsmeyer-Peppas			Hixson-Crowell	
	R^2	K_0	R_1^2	K_1	R_H^2	K_H	R_k^2	Kp	n	R^2	Ks
LS1	0.934	6.318	0.924	0.1750	0.982	25.02	0.962	27.861	0.443	0.961	0.186
LS2	0.905	6.239	0.953	0.1819	0.989	25.20	0.975	31.915	0.405	0.973	0.191
LS3	0.895	6.255	0.947	0.1934	0.983	25.32	0.958	34.119	0.381	0.969	0.198
LS4	0.884	6.459	0.867	0.2625	0.984	26.32	0.968	36.982	0.369	0.952	0.235
LD5	0.932	5.960	0.968	0.1404	0.992	23.75	0.985	25.585	0.462	0.977	0.160

Effect of osmogen concentration

The core formulations were prepared with various concentrations of osmogens. The drug release profile is shown in figure 5. It is observed that osmogent enhances the drug release of drug and thus had a direct effect on drug release. The concentrations of osmogen were 0, 25, 50, 75 and 100 mg/tablet for LD5, LS1, LS2, LS3 and LS4 respectively. The cumulative percentage drug release for LS1, LS2, LS3, LS4 and LD5 were 91.92, 92.48, 93.71, 98.26 and 85.89% respectively of lamivudine at the end of 12 hrs.

Effect of pore former

Release profile from prepared formulations is shown in figure 5. It is clearly evident that the level of sorbitol had a direct effect on drug release. As the level of pore former increases the membrane becomes more porous after coming contact with aqueous environment resulting in faster drug release.

Effect of membrane thickness

The osmotic pump coated tablets having varying the coating thickness are evaluated for drug release study. Release profile of lamivudine from these formulations is shown in figure 5. It is clearly evident that drug release decreases with increase in coating thickness of the semi permeable membrane.

Effect of osmotic pressure

The results of release studies of optimized formulation in media of different osmotic pressure indicated that the drug release is highly dependent on the osmotic pressure of the release media. The release was inversely related to the osmotic pressure of release media. This finding confirms that the mechanism of drug release is by osmotic pressure. The drug release for LS4 was found to be 90.54% for 30 atm, 81.46% for 60 atm and 72.67% for 90 atm respectively. It is shown in figure 6.




Figure 6. *In vitro* release profiles showing lamivudine release from optimized LS4 in different osmotic pressures

Effect of pH

The optimized formulation LS4 was subjected to *in vitro* drug release studies in buffers with different pH like pH 1.2, pH 6.8 and pH 7.4. It is observed that there is no significant difference in the release profile, demonstrating that the developed formulation shows pH independent release. It is shown in figure 7.




Figure 7. *In vitro* dissolution study of optimized formulation LS4 in various pH media

Effect of agitation intensity

The optimized formulation of LS4 batch was carried out in USP dissolution apparatus type-II at varying rotational speed (50, 100 and 150 rpm). It shows that the release of lamivudine from CPOP is independent of agitational intensity. Hence it can be expected that the release from the developed formulation will be independent of the hydrodynamic conditions of the absorption site. It is shown in figure 8.




Figure 8. *In vitro* dissolution study of optimized formulation LS4 in various agitation speed

SEM analysis

Before dissolution fewer pores were found in the coating membrane. But after dissolution comparatively more numbers of pores were found in the membrane might be due to leaching or removal of entrapped drug from the formulation. The porosity nature of the membrane was due to the presence of pore forming agent sorbitol in the formulation (Figures 9a and 9b).




Figure 9. (a) SEM image of LS4 before dissolution (b) SEM image of LS4 after dissolution

Stability Studies

From short term stability studies of optimized formulation LS4, it was confirmed that there was no significance changes in physical appearance, thickness, hardness, friability, weight variation drug content and % drug release.

Conclusion

CPOP tablets can be designed for controlled release of lamivudine using wet granulation technique. It was evident from the results that rate of drug release can be controlled through osmotic pressure of the core, the level of pore former. From the developed formulations the release of lamivudine

was best in LS4 formulation. The result of SEM studies confined the formation of pores in the membrane after coming into contact with the aqueous environment.

Acknowledgements

The authors would like to acknowledge the contributions of Pharmaceutics department, Faculty of Pharmacy, University College of Technology, Osmania University, Hyderabad, India for providing necessary facilities to carry out the research work. This study was part of a Ph.D thesis under Osmania University, Hyderabad.

References

1. Barre Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome(AIDS). *Science*. 1983; 220: 868-871.
2. UNAIDS. Review of data from People Living with HIV Stigma Index surveys conducted in more than 65 countries. 2016.
3. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. *J Infect Dis*. 2010; 15(202): 270-277. doi: 10.1086/655651
4. Chein YW. *Novel Drug Delivery Systems*. Marcel Dekker, Inc., New York, USA. 1992: 139-196.
5. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. *J Control Release*. 2000; 79: 7-27.
6. Richman DD. HIV chemotherapy. *Nature*. 2001; 410: 995-1001. doi: 10.1038/35073673
7. Jadav MM, Teraiya SR, Patel KN, Patel BA, Patel PA. Formulation and Evaluation of Oral Controlled Porosity Osmotic Pump Tablet of Zaltoprofen. *International Journal for Pharmaceutical Research Scholars*. 2012; 1(2): 254-267.
8. Edavalath S, Shivanand K, Prakasam K, Rao BP, Divakar G. Formulation development and optimization of controlled porosity osmotic pump tablets of diclofenac sodium. *Int J Pharm Pharm Sci*. 2011; 3(1): 80-87.
9. Banerjee A, Verma PRP, Gore S. Controlled porosity solubility modulated osmotic pump tablets of Gliclazide. *AAPS Pharm Sci Tech*. 2015; 16(3): 554-568.
10. Sahoo CK, Sahoo TK, Moharana AK, Panda KC. Formulation and optimization of porous osmotic pump based controlled release system of Residronate sodium for the treatment of postmenopausal osteoporosis. *International Journal of Pharmaceutical Sciences Review and Research*. 2012; 12(1): 118-122.
11. Sahoo CK, Sahoo NK, Rao SRM, Sudhakar M, Satyanarayana K. A review on controlled porosity osmotic pump tablets and its evaluation. *Bulletin of Faculty of Pharmacy, Cairo University*. 2015; 53 (2):1 95-205
12. Sunil SA, Srikanth MV, Rao NS, Balaji S, Murthy KVR. Design and evaluation of lornoxicam bilayered tablets for biphasic release. *Brazilian Journal of Pharmaceutical Sciences*. 2012; 48(4): 609-619.
13. Sahoo CK, Rao SRM, Sudhakar M. Evaluation of controlled porosity osmotic pump tablets: a review. *Research J. Pharm. and Tech*. 2015; 8(12): 119-125. doi: 10.5958/0974-360X.2015.00312.1
14. Pawar AH, Dhavale R. Development and evaluation of gastroretentive floating tablets of an antidepressant drug by thermoplastic granulation technique. *Beni-suef University Journal of Basic and Applied Sciences*. 2014; 3: 122-132. doi: 10.1016/j.bjbas.2014.05.005
15. Sahoo CK, Rao SRM, Sudhakar M, Kokkula S. The kinetic modeling of drug dissolution for drug delivery systems: an overview. *Der Pharmacia Lettre*. 2015; 7(9): 186-194.
16. Costa P, Lobo JMS. Modelling and comparison of dissolution profiles. *European Journal of Pharmaceutical Sciences*. 2001; 13: 123-133. doi: 10.1016/S0928-0987(01)00095-1

17. Kumaravelrajan R, Narayanan N, Suba V. Development and evaluation of controlled porosity osmotic pump for Nifedipine and Metoprolol combination. *Lipids Health Dis.* 2011; 10: 51. doi: 10.1186/1476-511X-10-51
18. Dasankoppa FS, Ningangowdar M, Sholapur H. Formulation and evaluation of controlled porosity osmotic pump for oral delivery of ketorolac. *J Basic Clin Pharm.* 2013; 4(1): 2-9. doi: 10.4103/0976-0105.109398
19. Kanagale P, Lohray BB, Misra A, Davadra P, Kini R. Formulation and Optimization of Porous Osmotic Pump based Controlled Release System of Oxybutynin. *AAPS Pharm Sci Tech.* 2007; 8(3): 1-7. doi: 10.1208/pt0803053
20. Shah N, Patel K. Design and development of controlled porosity osmotic tablets of captopril. *Journal of Pharmaceutical Science and Bioscientific Research.* 2013; 3(4): 145-150.
21. Rani M, Mishra B. Comparative *in vitro* and *in vivo* evaluation of matrix, osmotic matrix and osmotic pump tablets for controlled delivery of diclofenac sodium. *AAPS Pharm Sci Tech.* 2004; 5(4): 1-7. doi: 10.1208/pt050471
22. Maheswari U, Elango K, Chellakumari D, Saravanan K, Samy AJ. Formulation and evaluation of controlled porosity osmotic tablets of lornoxicam. *International Journal of Pharmaceutical Sciences and Research.* 2012; 3(6): 1625-1631. doi: 10.13040/IJPSR.0975-8232
23. Khan ZA, Tripathi R, Mishra B. Design and evaluation of enteric coated microporous osmotic pump tablet(ECMOPT) of quetiapine fumarate for the treatment of psychosis. *Acta Poloniae-Drug Research* 2012; 69(6): 1125-1136.
24. Sharma F, Jain H, Kanzariya V, Upadhyay U. Formulation and evaluation of controlled release osmotic tablet of metoprolol succinate. *Asian J Pharm Clin Res.* 2014; 7(3): 38-43.